Nano-X Imaging Ltd. Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd. filed a Form 6-K for August 2021, dated August 19, 2021. The filing reports a regulatory development concerning the company’s Nanox.ARC multi-source X-ray imaging device and is incorporated by reference into the company’s Form S-8 registration statement.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It focuses solely on the company’s FDA regulatory process and related forward-looking statements.
Material Changes and Regulatory Development
- On August 12, 2021, the FDA requested additional information regarding the company’s latest 510(k) submission for the multi-source Nanox.ARC.
- The 510(k) submission has been placed on hold pending the company’s complete response to the FDA’s list of deficiencies.
- The company’s response is due within 180 days of the FDA’s request.
- Management stated that it plans to respond by the deadline and continue optimizing and developing additional Nanox.ARC features.
- The company is considering submitting an additional 510(k) application for a next version of the multi-source Nanox.ARC during the fourth quarter of 2021, incorporating feedback from the FDA’s review of the first version.
Outlook, Risks, and Contingencies
The regulatory hold creates uncertainty regarding the timing and potential receipt of FDA clearance for the Nanox.ARC. The company’s proposed additional submission and development plans are subject to FDA feedback, technical feasibility, quality requirements, and regulatory approval.
- COVID-19 or similar public health disruptions could delay development, deployment, or regulatory clearance.
- Commercial success depends on demonstrating the technology’s feasibility, obtaining and maintaining regulatory approvals, securing qualified manufacturers and suppliers, and achieving market acceptance of the Nanox.ARC and proposed pay-per-scan model.
- Additional risks relate to third-party collaborations, global operations, and compliance with applicable quality and regulatory standards.
Key Facts for Investor Verification
- Verify the FDA’s August 12, 2021 request and the specific deficiencies identified.
- Confirm the deadline for the company’s response based on the 180-day period.
- Track whether the company submits the contemplated fourth-quarter 2021 510(k) application.
- Monitor subsequent FDA action, including clearance, additional requests, or further delays.
- Review later filings for financial resources and liquidity available to fund regulatory, development, manufacturing, and commercialization activities.